Active, Not Recruiting
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers - CA043-001
Uppdaterad:
17 april, 2024
|
ClinicalTrials.gov
Fas
Kön
Åldersintervall
Active, Not Recruiting
For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologic or cytologic confirmation of select solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy - Eastern Cooperative Oncology Group Performance Status of 0 or 1 - Participants must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to select solid tumor histologies Exclusion Criteria: - Participants with active, known or suspected autoimmune disease - Participants with other active malignancy requiring concurrent intervention - Participants with primary CNS malignancies or tumors with CNS metastasis as the only site of disease, will be excluded Other protocol defined inclusion/exclusion criteria could apply
Vi rekommenderar att du kontaktar BMS för att rapportera biverkningar.
Biverkningar (oönskade händelser) och andra rapporterbara händelser definieras här
För att rapportera biverkningar (oönskade händelser) eller reklamera ett läkemedel: Medicinsk information
466-SE-2100058